Active	Status	Sponsor type	Region	Phase	Filter
5 Active 37 Inactive 42 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Provenge (sipuleucel-T) / Bausch Health
ProvONE, NCT06134232: Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T	Not yet recruiting	3	400	NA	Sipuleucel-T Injection	Dendreon	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	12/31	06/32
ProVent, NCT03686683: Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer	Active, not recruiting	3	450	US	sipuleucel-T	Dendreon, PRA Health Sciences	Adenocarcinoma of the Prostate	12/23	02/24
NCT05751941: Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer	Recruiting	2	26	US	Abiraterone, Enzalutamide, Xtandi, Apalutamide, Sipuleucel-T, Provenge	H. Lee Moffitt Cancer Center and Research Institute, Dendreon	Prostate Cancer, Metastatic Prostate Cancer	10/25	10/25
NCT06100705: Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC	Recruiting	2	26	US	Testosterone Cypionate, DEPO-Testosterone, Sipuleucel-T, Provenge	Yale University, Dendreon	Metastatic Castration-resistant Prostate Cancer	12/27	03/28
OU-SCC-EXCITE, NCT05806814: Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer	Recruiting	1	12	US	Sipuleucel-T, PROVENGE	University of Oklahoma, Dendreon	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	11/24	11/24